Skip to main content

AMR Action Fund invests in new antibiotics developed by BioVersys

| News

AMR Action Fund invests in new antibiotics developed by BioVersys


The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The world’s second largest foundation for the promotion of medical research is seeking to launch two to four antimicrobials to combat resistant bacteria on the market by 2030.

The BioVersys team receives the first European-based investment of the AMR Action Fund (img: BioVersys)

BioVersys is the first European company to receive funding for its clinical trials from the AMR Action Fund. According to a press release, the AMR Action Fund is the world’s largest public-private partnership for investments in biotechnology companies and is seeking to facilitate the market launch of two to four antimicrobials by 2030. To this end, the fund is now placing its faith in BioVersys and joined a significantly oversubscribed Series C financing round carried out by the Basel-based firm. In the process, BioVersys generated gross proceeds of 32.6 million Swiss francs, further details of which can be found in a press release of its own.

The clinical phase biotechnology company is a spin-off from the Basel-based Department of Biosystems Science and Engineering of the Swiss Federal Institute of Technology in Zurich (ETH). The company is headquartered at Tech Park Basel and develops antimicrobials that target some of the world’s most threatening drug-resistant bacteria. According to Dr. Marc Gitzinger, CEO and founder of BioVersys AG, the AMR Action Fund will be “a valuable partner as we advance our programs into Phase 2 clinical trials and beyond so that these treatments can reach patients as soon as possible”.

AMR Action Fund’s European headquarters in Basel

“The candidates in its pipeline have the potential to significantly improve care for patients suffering from intractable infections for which there are few, if any, effective treatments”, comments Dr. Martin Heidecker, Chief Investment Officer of the AMR Action Fund, in the press release. “We are eager to work with the BioVersys team to help bring these therapeutics to patients”, he adds.

The concept of the AMR Action Fund, founded in 2020 and headquartered in Boston, with European headquarters in Basel, was developed by the International Federation of Pharmaceutical Manufacturers & Associations and its biopharmaceutical member firms in collaboration with the World Health Organization (WHO), the European Investment Bank (EIB) and the Wellcome Trust. The AMR Action Fund has 1 billion US dollars of venture capital at its disposal.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.